Intended For US Audiences Only.

WE ARE ALWAYS HERE TO PROVIDE THE MOST UP-TO-DATE AND ACCURATE INFORMATION ON OUR PRODUCTS AND COMPANY

WHAT IS THE DOSING SCHEDULE?

Layer_1 (3)BIVIGAM is usually given every 3 to 4 weeks. Fewer doses mean more treatment-free days for you! Your healthcare provider may change your dosing schedule, depending on how your body reacts to the medicine.

ADMA Biologics
Corporate Headquarters

ADMA Biologics
465 Route 17 South
Ramsey, NJ 07446

T: 201-478-5552
F: 201-478-5553


ADMA Biologics
Florida Campus

ADMA Biologics
5800 Park of Commerce Blvd, NW
Boca Raton, FL 33487

T: 561-989-5800
F: 561-989-5801

For General Inquiries, please contact:
Toll free: 800-458-4244, option 5
Email: CustomerService@admabio.com

For Medical Information, please contact:
Toll free: 800-458-4244, option 2
Email: MA@admabio.com

For adverse events reporting, please contact:
Toll free: 800-458-4244, option 2
Email: PV@admabio.com

For product quality complaints, please contact:
Toll free: 800-458-4244, option 3
Email: PV@admabio.com

Contact the FDA (MedWatch):
Toll free: 1-800-FDA-1088
Fax: 1-800-FDA-0178

For General Inquiries, please contact:
Toll free: 800-458-4244, option 5
Email: CustomerService@admabio.com

For Medical Information, please contact:
Toll free: 800-458-4244, option 2
Email: MA@admabio.com

For adverse events reporting, please contact:
Toll free: 800-458-4244, option 2
Email: PV@admabio.com

For product quality complaints, please contact:
Toll free: 800-458-4244, option 3
Email: PV@admabio.com

Contact the FDA (MedWatch):
Toll free: 1-800-FDA-1088
Fax: 1-800-FDA-0178

Logo for ADMA Biologics

Important Safety Information for BIVIGAM®

BIVIGAM is an Immune Globulin Intravenous (Human), 10% Liquid, indicated for the treatment of primary humoral immunodeficiency (PI). This includes, but is not limited to, the humoral immune defect in common variable immunodeficiency (CVID), X linked agammaglobulinemia, congenital agammaglobulinemia, Wiskott-Aldrich syndrome, and severe combined immunodeficiencies (SCID).

WARNING: RISK OF BLOOD CLOTS (THROMBOSIS), POOR KIDNEY FUNCTION, AND KIDNEY FAILURE

  • Blood clots may happen with intravenous immune globulin products, including BIVIGAM. Before taking BIVIGAM, talk to your doctor if you:
    • Are of advanced age
    • Are unusually sedentary (long periods of sitting down or inactive)
    • Have a history of blood clots in the veins or arteries, cardiovascular (heart) problems or previous history of stroke
    • Are taking estrogen-containing medicines (birth control pills, hormone replacement therapy)
    • Have a permanent intravenous (IV) catheter
    • Have hyperviscosity (poor blood flow) of the blood (diseases such as multiple myeloma or other causes of elevated proteins in the blood)
  • Kidney problems, kidney failure, and death are more common in people who are taking human immune globulin products, especially those containing sucrose (sugar). BIVIGAM does not contain sucrose. Let your doctor know if you have kidney disease or diseases with kidney involvement, have a history of diabetes, or are older than 65 years of age. Your doctor should check your hydration level, blood infection risk, protein levels, and if you are taking any drugs that may damage your kidneys.
  • If you are at risk for blood clots or kidney problems, your doctor should adjust your starting dose of BIVIGAM and monitor your blood flow.

Tap for important safety information for BIVIGAM